CABA stock forecast
Our latest prediction for Cabaletta Bio Inc's stock price was made on the Jan. 12, 2021 when the stock price was at 14.53$.
In the short term (2weeks), CABA's stock price should underperform the market by -3.86%. During that period the price should oscillate between -12.53% and +12.68%.
In the medium term (3months), CABA's stock price should underperform the market by -3.83%. During that period the price should oscillate between -38.19% and +33.20%.Get email alerts
Create a solid portfolio with CABA
About Cabaletta Bio Inc
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA) platform, in combination with Cabaletta's proprietary technology, utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company's lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. The Company's lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -1.46$ per share.
The book value per share is 4.88$
Three months stock forecastJan. 12, 2021
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|